ClinicalTrials.gg
TerminatedNCT03978780Updated Nov 16, 2026

Erector Spinae Block vs. Placebo Block Study

An interventional study of Erector spinae plane block and Placebo Block in Breast Cancer, Nerve Block and Regional Anesthesia, sponsored by Women's College Hospital. Terminated at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Women's College Hospital · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
The study team has decided not to proceed with this study idea, as it is already established as standard practice at Women's College Hospital and therefore does not meet criteria for evaluation as a research study.
Updated Nov 16, 2026Now TerminatedStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 907 studies in Breast Neoplasms with a site in Canada — 139 open to participants now, 257 under way, 81 of them phase 3. Breast Neoplasms · Canada.

Enrollment
557th of 787
60 · median 155
Started
2026
with 23 others
No phase
204 of 907
37 open now
Registered
627th of 907
by date

Among the 907 studies in Breast Neoplasms with a site in Canada, this one is the 557th largest by enrollment of the 787 interventional ones that give a count, is one of 24 that started in 2026, is one of 204 with no phase, and was the 627th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

139 of the 907 studies in Breast Neoplasms with a site in Canada are open now. Recruiting first, the newest first:

134 more — sign in →

All 139 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 907 studies in Breast Neoplasms with a site in Canada, or all of them as a file.
02

Study summary

Regional anaesthesia combined with general anaesthesia has become common in the perioperative management of breast cancer surgery patients. Regional techniques have been recognised to provide excellent post-operative analgesia. It enhances multi-modal analgesia regimes while being opioid sparing, reducing incidence of post-operative nausea and vomiting and allowing earlier mobilisation/discharge and improving treatment success. Therefore identifying the correct regional anaesthetic technique for this group of patients is important in providing optimum peri-operative care.

Read the detailed description

The ultrasound-guided erector spinae plane (ESP) block has been recently described for the successful management of thoracic neuropathic pain. The erector spinae muscle is formed by the spinalis, longissimus thoracis, and iliocostalis muscles that run vertically in the back. The ESP block is performed by depositing the local anaesthetic in the fascial plane, deep to the erector spinae muscle, at the tip of the transverse process of the vertebra. Indirect access to the paravertebral space is gained providing analgesia without the risk of needle injury to structures in close proximity. Cadaveric studies have shown both ventral and dorsal rami of thoracic spinal nerves are affected when local anaesthetic is injected deep to the erector spinae muscle. The erector spinae muscle extends along the thoracolumbar spine allowing extensive cranio-caudal spread. The ventral ramus (intercostal nerve) is divided into the anterior and lateral branches. Its terminal branches provide the sensory innervation of the entire anterolateral wall. The dorsal ramus is divided into 2 terminal branches and it gives the sensory innervation to the posterior wall. Anterior spread of the local anaesthetic to the paravertebral space through the costotransverse foramina and the intertransverse complex provides both visceral and somatic analgesia.

While recent evidence supports statistically significant reductions in pain and opioid consumption among patients who receive an ESP block compared to systemic analgesia alone, the clinical significance of these differences are questionable the effect of ESP block on the patients' quality of recovery following ambulatory breast cancer surgery remains unclear.

Therefore, our objective is to determine whether or not the addition of an ESP block provides both superior analgesia and quality of recovery in patients undergoing ambulatory breast cancer surgery compared to systemic analgesia alone. We hypothesis that patients who received a preoperative ESP block will afford superior postoperative analgesia and improve the quality of recovery over the first 24 hours following surgery compared to those who receive a sham block for their ambulatory breast cancer surgery.

03

Conditions studied

  • Breast Cancer
  • Nerve Block
  • Regional Anesthesia
  • Neuromuscular Blockade

Browse trials for

Keywords

  • Spinae fascial plane block
  • Breast surgery
  • interfascial plane block
  • erector spinae block
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • : I-III
  • \< 35 kg/m2
  • Day surgery procedure

Exclusion criteria

Exclusion Criteria:

  • Prior ipsilateral breast surgery, excluding lumpectomy
  • Pre-existing neurological deficit or peripheral neuropathy involving the ipsilateral chest
  • Severe, poorly controlled cardiac conditions, significant arrhythmias, severe valvular heart diseases
  • Severe, poorly controlled respiratory conditions (severe , severe interstitial lung disease, severe / poorly controlled asthma)
  • to regional anaesthesia (e.g. bleeding diathesis, coagulopathy, sepsis, infection at the site of potential needle puncture on the posterior chest)
  • Patient refusal
  • Chronic pain disorder
  • Chronic opioid use (≥30 mg oxycodone / day)
  • Contraindication (or allergy) to a component of multi-modal analgesia protocol
  • Allergy to amide local anaesthetics used in nerve blocks
  • Contraindications to any of the components of the standardized general anaesthesia
  • Significant psychiatric disorder that would preclude objective study assessment
  • Pregnancy/ women with nursing infants
  • Unable to provide
  • Unable to speak and read English
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Placebo comparator
    Control Group

    Patients randomised to the Control group will then receive a sham subcutaneous injection of 0.5ml normal saline injected at the same site as the ESP block (see above) under ultrasound guidance to stimulate a real block procedure.

    Procedure: Placebo Block

  • Experimental
    Erector spinae plane (ESP) block group

    Local anaesthetic infiltration utilising 1% lidocaine will occur, and an 80mm 22G block needle will be inserted using an in-plane cranial to caudad approach, the needle will be advanced to target the interfascial plane deep to the erector spinae muscle at the T2 transverse process. Once the needle tip is in the correct position, 20 ml of the local anaesthetic (ropivacaine 0.5% with 1:400,000 epinephrine) will be administered slowly in 5 ml aliquots under frequent aspiration and correct spread in the interfascial plane will be observed.

    Procedure: Erector spinae plane block

Interventions

  • ProcedureErector spinae plane block

    80mm 22G block needle will be inserted using an in-plane cranial to caudad approach, the needle will be advanced to target the interfascial plane deep to the erector spinae muscle at the T2 transverse process. Once the needle tip is in the correct position, 20 ml of the local anaesthetic (ropivacaine 0.5% with 1:400,000 epinephrine) will be administered slowly in 5 ml aliquots under frequent aspiration and correct spread in the interfascial plane will be observed.

  • ProcedurePlacebo Block

    Patients randomised to the Control group will then receive a sham subcutaneous injection of 0.5ml normal saline injected at the same site as the ESP block under ultrasound guidance to stimulate a real block procedure.

06

What researchers measure

Primary outcomes

  1. Acute postoperative pain at rest

    Following breast surgery, measured as an area under the curve (AUC) of rest pain scores VAS scale where 0 corresponds to no pain, and 10 corresponds to worst pain imaginable

    Time frame: 24 hours postoperatively

  2. Quality of postoperative recovery (QoR 15)

    Quality of recovery at 24 hours: questionnaire (0-10, where 0 = none of the time \[poor\] and 10 = all of the time \[excellent\])

    Time frame: 24 hours post-surgery

Secondary outcomes

  1. Postoperative pain scores

    VAS scale where 0 corresponds to no pain, and 10 corresponds to worst pain imaginable

    Time frame: 0, 6, 12, 18, 24 and 48 hours post-operatively

  2. Intraoperative opioid consumption

    Cumulative oral morphine equivalent after surgery

    Time frame: During the procedure

  3. Postoperative opioid consumption

    Cumulative oral morphine equivalent after surgery

    Time frame: 12,24,48 hours, 7 days postoperative

  4. Duration of phase I (PACU) and phase II (surgical day care, SDC) stay

    How fast is the recovery is-expressed in minutes

    Time frame: From end of surgical procedure to 24 hours after surgery

  5. Opioid-related side effects

    Risk of opioid-related side effects(nausea, vomiting, pruritis)

    Time frame: End of surgical procedure to 48 hours after surgery

  6. Persistent post surgical pain DN4 screening tool

    Satisfaction with pain management. Is prescribed pain medication enough?

    Time frame: 3 months post operatively

  7. Block-related complications

    bruising at injection site, numbness over lateral chest, weakness of shoulder or arm, pain/swelling at injection site

    Time frame: End of surgical procedure to 48 hours after surgery

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Apr 2026 to primary completion in Apr 2026, 0 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: start Jun 2026 → Apr 2026, primary completion Jun 2027 → Apr 2026 and completion Jan 2028 → Apr 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2019
First posted
Jun 7, 2019
StartActual
Apr 30, 2026was Jun 2026
Primary completionActual
Apr 30, 2026was Jun 2027
CompletionActual
Apr 30, 2026was Jan 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Terminated The study team has decided not to proceed with this study idea, as it is already established as standard practice at Women's College Hospital and therefore does not meet criteria for evaluation as a research study.
changed Nov 16, 2026
Start date
Jun 2026→Apr 30, 2026 (actual)
Nov 16, 2026
Primary completion
Jun 2027→Apr 30, 2026 (actual)
Nov 16, 2026
Study completion
Jan 2028→Apr 30, 2026 (actual)
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Not yet recruiting→Terminated
    Why stopped The study team has decided not to proceed with this study idea, as it is already established as standard practice at Women's College Hospital and therefore does not meet criteria for evaluation as a research study.
    Start date Jun 2026→Apr 30, 2026 (now actual)
    Primary completion Jun 2027→Apr 30, 2026 (now actual)
    Study completion Jan 2028→Apr 30, 2026 (now actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT03978780
Lead sponsor
Women's College Hospital
Responsible party
Sponsor
First posted
Jun 7, 2019
Start date
Apr 30, 2026
Primary completion
Apr 30, 2026
Completion
Apr 30, 2026
Last update
Nov 16, 2026

Study contacts

Richard Brull, MD,FRCPC
principal investigator · Women's College Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion